JP2024513392A - コンジュゲートされたヘプシジン模倣物 - Google Patents
コンジュゲートされたヘプシジン模倣物 Download PDFInfo
- Publication number
- JP2024513392A JP2024513392A JP2023560497A JP2023560497A JP2024513392A JP 2024513392 A JP2024513392 A JP 2024513392A JP 2023560497 A JP2023560497 A JP 2023560497A JP 2023560497 A JP2023560497 A JP 2023560497A JP 2024513392 A JP2024513392 A JP 2024513392A
- Authority
- JP
- Japan
- Prior art keywords
- lys
- cys
- substituted
- pharmaceutically acceptable
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026038265A JP2026088199A (ja) | 2021-04-01 | 2026-03-10 | コンジュゲートされたヘプシジン模倣物 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163169538P | 2021-04-01 | 2021-04-01 | |
| US202163169527P | 2021-04-01 | 2021-04-01 | |
| US202163169533P | 2021-04-01 | 2021-04-01 | |
| US63/169,538 | 2021-04-01 | ||
| US63/169,527 | 2021-04-01 | ||
| US63/169,533 | 2021-04-01 | ||
| US202263325323P | 2022-03-30 | 2022-03-30 | |
| US63/325,323 | 2022-03-30 | ||
| PCT/US2022/022809 WO2022212696A1 (en) | 2021-04-01 | 2022-03-31 | Conjugated hepcidin mimetics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026038265A Division JP2026088199A (ja) | 2021-04-01 | 2026-03-10 | コンジュゲートされたヘプシジン模倣物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024513392A true JP2024513392A (ja) | 2024-03-25 |
| JP2024513392A5 JP2024513392A5 (cg-RX-API-DMAC7.html) | 2025-03-06 |
Family
ID=83456776
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560497A Pending JP2024513392A (ja) | 2021-04-01 | 2022-03-31 | コンジュゲートされたヘプシジン模倣物 |
| JP2026038265A Pending JP2026088199A (ja) | 2021-04-01 | 2026-03-10 | コンジュゲートされたヘプシジン模倣物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026038265A Pending JP2026088199A (ja) | 2021-04-01 | 2026-03-10 | コンジュゲートされたヘプシジン模倣物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250277012A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4314017A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2024513392A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022249095A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3213688A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202304951A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022212696A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4091624A1 (en) | 2013-03-15 | 2022-11-23 | Protagonist Therapeutics, Inc. | Hepcidin analogues and uses thereof |
| CA2949215C (en) | 2014-05-16 | 2023-03-14 | Protagonist Therapeutics, Inc. | .alpha.4.beta.7 integrin thioether peptide antagonists |
| SG10201810154WA (en) | 2014-07-17 | 2018-12-28 | Protagonist Therapeutics Inc | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| WO2018022937A1 (en) | 2016-07-27 | 2018-02-01 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 and their use to treat inflammatory diseases |
| WO2019157268A1 (en) | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| MX2022008740A (es) | 2020-01-15 | 2022-09-23 | Janssen Biotech Inc | Peptidos inhibidores del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias. |
| SMT202500254T1 (it) | 2020-01-15 | 2025-09-12 | Janssen Biotech Inc | Inibitori peptidici del recettore dell'interleuchina-23 e loro uso per trattare malattie infiammatorie |
| AU2021383828A1 (en) | 2020-11-20 | 2023-07-06 | Janssen Pharmaceutica Nv | Compositions of peptide inhibitors of interleukin-23 receptor |
| KR20240034224A (ko) | 2021-07-14 | 2024-03-13 | 얀센 바이오테크 인코포레이티드 | 인터류킨-23 수용체의 지질화된 펩티드 억제제 |
| US20250170216A1 (en) * | 2022-02-02 | 2025-05-29 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| EP4472995A4 (en) * | 2022-02-02 | 2025-11-19 | Protagonist Therapeutics Inc | Conjugated hepcidin mimetics |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016521257A (ja) * | 2013-03-15 | 2016-07-21 | プロタゴニスト セラピューティクス, インコーポレイテッド | ヘプシジン類似体及びその使用 |
| JP2017523959A (ja) * | 2014-06-27 | 2017-08-24 | プロタゴニスト セラピューティクス, インコーポレイテッド | ヘプシジンおよびミニ−ヘプシジンアナログおよびその使用 |
| WO2019157268A1 (en) * | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002079235A2 (en) * | 2001-03-30 | 2002-10-10 | University Of Copenhagen | Compositions and methods for modulating guanylyl cyclase signaling receptor (gc-c) activity and for treating meniere's disease |
| CA3009834A1 (en) * | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| WO2018128828A1 (en) * | 2016-12-23 | 2018-07-12 | Bayer Healthcare Llc | Novel hepcidin mimetics and uses thereof |
| US20220372099A1 (en) * | 2019-09-03 | 2022-11-24 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
| IL299530A (en) * | 2020-07-28 | 2023-02-01 | Protagonist Therapeutics Inc | Psidine is a conjugated mimetic |
-
2022
- 2022-03-31 WO PCT/US2022/022809 patent/WO2022212696A1/en not_active Ceased
- 2022-03-31 AU AU2022249095A patent/AU2022249095A1/en active Pending
- 2022-03-31 US US18/284,835 patent/US20250277012A1/en active Pending
- 2022-03-31 EP EP22782206.1A patent/EP4314017A4/en active Pending
- 2022-03-31 JP JP2023560497A patent/JP2024513392A/ja active Pending
- 2022-03-31 CA CA3213688A patent/CA3213688A1/en active Pending
- 2022-04-01 TW TW111112892A patent/TW202304951A/zh unknown
-
2026
- 2026-03-10 JP JP2026038265A patent/JP2026088199A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016521257A (ja) * | 2013-03-15 | 2016-07-21 | プロタゴニスト セラピューティクス, インコーポレイテッド | ヘプシジン類似体及びその使用 |
| JP2017523959A (ja) * | 2014-06-27 | 2017-08-24 | プロタゴニスト セラピューティクス, インコーポレイテッド | ヘプシジンおよびミニ−ヘプシジンアナログおよびその使用 |
| WO2019157268A1 (en) * | 2018-02-08 | 2019-08-15 | Protagonist Therapeutics, Inc. | Conjugated hepcidin mimetics |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022212696A1 (en) | 2022-10-06 |
| TW202304951A (zh) | 2023-02-01 |
| CA3213688A1 (en) | 2022-10-06 |
| EP4314017A4 (en) | 2025-09-10 |
| AU2022249095A1 (en) | 2023-10-12 |
| JP2026088199A (ja) | 2026-05-28 |
| EP4314017A1 (en) | 2024-02-07 |
| US20250277012A1 (en) | 2025-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12234300B2 (en) | Conjugated hepcidin mimetics | |
| US11472842B2 (en) | Analogues of hepcidin mimetics with improved in vivo half lives | |
| JP2023540679A (ja) | コンジュゲートされたヘプシジン模倣物 | |
| JP7849383B2 (ja) | コンジュゲートされたヘプシジン模倣物 | |
| AU2022249095A1 (en) | Conjugated hepcidin mimetics | |
| WO2022212698A1 (en) | Conjugated hepcidin mimetics | |
| WO2023150630A2 (en) | Conjugated hepcidin mimetics | |
| EP4472995A2 (en) | Conjugated hepcidin mimetics | |
| CN117730089A (zh) | 结合型铁调素模拟物 | |
| CN117136192A (zh) | 缀合的铁调素模拟物 | |
| CN117813313A (zh) | 结合型铁调素模拟物 | |
| WO2026060110A1 (en) | Dual- and tri-agonist compounds for obesity & t2dm |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250226 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250226 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251219 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260310 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260513 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260806 |